MIL60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy
and safety of MIL60 with bevacizumab as first-line treatment when combined with standard
chemotherapy (paclitaxel/carboplatin) in treatment-naive patients with advanced or recurrent
non-squamous NSCLC.